Targeting the MDM2-p53 Pathway in Biliary Tract Cancer: Emerging Data and Implications for Future Clinical Practice

Gain in-depth knowledge on the role of the MDM2/p53 pathway in biliary tract cancer with an expert-authored module and commentary on the rationale for targeting this signaling pathway and the available efficacy and safety data with investigational MDM2 inhibitors in biliary tract cancer.

Share

Program Content

Activities

Role of the MDM2-p53 Pathway in BTC
Targeting the MDM2-p53 Pathway in Biliary Tract Cancer: Emerging Data and Implications for Future Clinical Practice
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: August 29, 2024

Expires: February 28, 2025

Activities

Role of the MDM2-p53 Pathway in BTC
Targeting the MDM2-p53 Pathway in Biliary Tract Cancer: Emerging Data and Implications for Future Clinical Practice
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: August 29, 2024

Expires: August 28, 2025

Activities

MDM2/p53 Signaling in BTC
Targeting the MDM2/p53 Signaling Pathway in Biliary Tract Cancers: Rationale and Current Status
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 09, 2024

Expires: August 08, 2025

Faculty

cover img faculity

Patricia LoRusso, DO, PhD(h)

Associate Center Director, Experimental Therapeutics
Director, Early Phase Clinical Trials Program
Yale Cancer Center
Yale University
New Haven, Connecticut

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.